These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12660500)

  • 1. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy.
    Saunders RN; Bicknell GR; Nicholson ML
    Transplantation; 2003 Mar; 75(6):772-80. PubMed ID: 12660500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and structural consequences of early renal allograft injury.
    Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
    Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of combined rapamycin/cyclosporine on the changes in pro-fibrotic gene expression that occur during the development of allograft vasculopathy in rats, compared with cyclosporine or rapamycin in isolation.
    Murphy GJ; Bicknell GR; Nicholson ML
    Transpl Int; 2003 May; 16(5):347-53. PubMed ID: 12759727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants.
    Bicknell GR; Williams ST; Shaw JA; Pringle JH; Furness PN; Nicholson ML
    Br J Surg; 2000 Nov; 87(11):1569-75. PubMed ID: 11091247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study.
    Han F; Wu J; Huang H; Zhang X; He Q; Wang Y; Wang S; Wang H; Chen J
    Exp Clin Transplant; 2011 Feb; 9(1):42-9. PubMed ID: 21605022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H; Cisterne JM; Land W; Wramner L; Squifflet JP; Abramowicz D; Campistol JM; Morales JM; Grinyo JM; Mourad G; Berthoux FC; Brattström C; Lebranchu Y; Vialtel P
    Transplantation; 2000 Apr; 69(7):1252-60. PubMed ID: 10798738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity.
    Khanna A; Plummer M; Bromberek C; Bresnahan B; Hariharan S
    Kidney Int; 2002 Dec; 62(6):2257-63. PubMed ID: 12427154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
    Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
    Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function.
    Hueso M; Bover J; Serón D; Gil-Vernet S; Sabaté I; Fulladosa X; Ramos R; Coll O; Alsina J; Grinyó JM
    Transplantation; 1998 Dec; 66(12):1727-31. PubMed ID: 9884267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of acute rejection on expression of fibrosis associated genes in renal transplant recipients.
    White SA; Bicknell GR; Jain S; Williams ST; Doughman T; Furness P; Nicholson ML
    Transplant Proc; 2000 Feb; 32(1):19-20. PubMed ID: 10700949
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation.
    Kahan BD; Podbielski J; Napoli KL; Katz SM; Meier-Kriesche HU; Van Buren CT
    Transplantation; 1998 Oct; 66(8):1040-6. PubMed ID: 9808489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results.
    Ferreira AN; Machado PG; Felipe CR; Motegi SA; Hosaka BH; Tanaka MK; Kamura LA; Park SI; Garcia R; Franco M; Alfieri F; Casarini DE; Tedesco-Silva H; Medina-Pestana JO
    Clin Transplant; 2005 Oct; 19(5):607-15. PubMed ID: 16146551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
    Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection.
    Brook NR; White SA; Waller JR; Bicknell GR; Nicholson ML
    Br J Surg; 2003 Aug; 90(8):1009-14. PubMed ID: 12905557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
    Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
    Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.